Cellectis Sa Stock Total Debt
| CLLS Stock | USD 3.48 0.01 0.29% |
Fundamental analysis of Cellectis allows traders to better anticipate movements in Cellectis' stock price by examining its financial health and performance throughout various phases of its business cycle.
Total Debt To Capitalization is likely to gain to 0.43 in 2025. Cellectis | Total Debt | Build AI portfolio with Cellectis Stock |
Cellectis SA Company Total Debt Analysis
Cellectis' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Cellectis Total Debt | 91.46 M |
Most of Cellectis' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectis SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cellectis Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Cellectis is extremely important. It helps to project a fair market value of Cellectis Stock properly, considering its historical fundamentals such as Total Debt. Since Cellectis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectis' interrelated accounts and indicators.
Click cells to compare fundamentals
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Cellectis Net Debt
Net Debt |
|
Based on the latest financial disclosure, Cellectis SA has a Total Debt of 91.46 M. This is 96.68% lower than that of the Biotechnology sector and 71.84% lower than that of the Health Care industry. The total debt for all United States stocks is 98.28% higher than that of the company.
Cellectis Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectis' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics of similar companies.Cellectis is currently under evaluation in total debt category among its peers.
Cellectis Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cellectis from analyzing Cellectis' financial statements. These drivers represent accounts that assess Cellectis' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cellectis' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.3B | 379.2M | 96.8M | 160.4M | 151.7M | 144.1M | |
| Enterprise Value | 1.1B | 295.3M | 82.0M | 108.7M | 99.9M | 94.9M |
Cellectis ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cellectis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cellectis' managers, analysts, and investors.Environmental | Governance | Social |
Cellectis Institutional Holders
Institutional Holdings refers to the ownership stake in Cellectis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cellectis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cellectis' value.| Shares | Wells Fargo & Co | 2025-06-30 | 17.1 K | Harbour Investments, Inc. | 2025-06-30 | 4.5 K | Rhumbline Advisers | 2025-06-30 | 1.9 K | Jpmorgan Chase & Co | 2025-06-30 | 1.8 K | Hanson Mcclain Inc | 2025-06-30 | 500 | Pom Investment Strategies, Llc | 2025-06-30 | 495 | Principal Securities Inc | 2025-06-30 | 179 | Advisor Group Holdings, Inc. | 2025-06-30 | 100.0 | Bank Of America Corp | 2025-06-30 | 77.0 | Long Focus Capital Management, Llc | 2025-06-30 | 4.7 M | B Group, Inc | 2025-06-30 | 3.3 M |
Cellectis Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0743 | ||||
| Profit Margin | (0.93) % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | 237.04 M | ||||
| Shares Outstanding | 72.33 M | ||||
| Shares Owned By Institutions | 18.76 % | ||||
| Number Of Shares Shorted | 273.05 K | ||||
| Price To Earning | (14.84) X | ||||
| Price To Book | 3.53 X | ||||
| Price To Sales | 5.47 X | ||||
| Revenue | 41.51 M | ||||
| Gross Profit | 63.44 M | ||||
| EBITDA | (15.84 M) | ||||
| Net Income | (36.76 M) | ||||
| Cash And Equivalents | 153.13 M | ||||
| Cash Per Share | 3.37 X | ||||
| Total Debt | 91.46 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | 22.99 M | ||||
| Short Ratio | 1.69 X | ||||
| Earnings Per Share | (0.59) X | ||||
| Target Price | 7.2 | ||||
| Number Of Employees | 216 | ||||
| Beta | 3.07 | ||||
| Market Capitalization | 347.01 M | ||||
| Total Asset | 383.54 M | ||||
| Retained Earnings | (329.61 M) | ||||
| Working Capital | 120.8 M | ||||
| Current Asset | 51 M | ||||
| Current Liabilities | 26.28 M | ||||
| Net Asset | 383.54 M |
About Cellectis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectis SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.